Podcast

Speaking of Urology: A HIFU expert discusses his treatment criteria

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.

Be sure to listen our first episode as well:

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Dr Louise Kostos answers a question during a Zoom video interview
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos discusses PSA kinetics in mHSPC
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Related Content
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: @ Dr_Microbe - stock.adobe.com
April 10th 2025

Polygenic risk score may identify more clinically significant PCa than PSA, MRI

Hannah Clarke
"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice – we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says Professor Ros Eeles.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
FDA updates in urology: March 2025
April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
© 2025 MJH Life Sciences

All rights reserved.